LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

Post-LOE

amoxicillin; clarithromycin; lansoprazole

Novartis

ANDAORALCAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS

Approved

Mar 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) (amoxicillin; clarithromycin; lansoprazole) by Novartis is [see microbiology ()] . Approved for infections due to susceptible strains of designated microorganisms, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli and 3 more indications. First approved in 2014.

Drug data last refreshed 19h ago

Mechanism of Action

[see Microbiology ()] .

Indications (6)

infections due to susceptible strains of designated microorganisms the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species

Worked on LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.